Meridian Management’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-9,280
Closed -$1.92M 94
2024
Q2
$1.92M Sell
9,280
-66
-0.7% -$15K 0.53% 40
2024
Q1
$2.53M Buy
9,346
+131
+1% +$31.3K 0.69% 38
2023
Q4
$2.05M Buy
9,215
+238
+3% +$46.8K 0.58% 38
2023
Q3
$1.76M Buy
+8,977
New +$1.84M 0.57% 38

Other funds holding CRL

Meridian Management's CRL Position: Q3 2024 in Review

Meridian Management sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 9,280 shares — an estimated $1.92M sold.

Meridian Management first reported a position in CRL in Q3 2023 and held it in 4 quarters. The position peaked at $2.53M in Q1 2024. 627 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Meridian Management reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Meridian Management sold 9,280 Charles River Laboratories shares in Q3 2024, an estimated $1.92M.
  • Meridian Management first reported a position in Charles River Laboratories in Q3 2023 and held it in 4 quarters.
  • Meridian Management's Charles River Laboratories position peaked at $2.53M in Q1 2024.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Meridian Management's 13F filing for Q3 2024, filed 4 Nov 2024.